Last updated: March 2026
A quick-reference guide comparing the plasma half-lives of 12 commonly studied research peptides, from ultra-short-acting compounds measured in minutes to engineered molecules that persist for days.
Part of the PeptidesATX Research Hub
Looking for research compounds used in these studies?
Explore verified research peptides in our shop.
In pharmacokinetic research, half-life (t½) is the time required for the plasma concentration of a compound to decrease by 50% from its peak level. For peptides, this parameter is shaped by enzymatic degradation, renal clearance, molecular size, and structural modifications designed to extend circulation time.
Understanding half-life is essential for designing research protocols. It determines how frequently a peptide must be administered to maintain target plasma concentrations, influences steady-state calculations, and affects how researchers interpret time-dependent biological responses. A peptide with a 2-minute half-life behaves very differently in experimental models than one engineered to circulate for 7 days.
The values below represent approximate plasma half-lives based on published preclinical and clinical pharmacokinetic data. Actual values vary depending on species, route of administration, dose, and assay methodology. These figures are provided as a research reference, not as dosing guidance. For a full index of peptide pharmacology guides and research resources, see the PeptidesATX Research Library.
| Peptide | Approx. Half-Life | Category | Research Notes | Links |
|---|---|---|---|---|
| Semaglutide | ~7 days (168 h) | Long | Fatty acid acylation enables albumin binding, dramatically reducing renal clearance. Longest-acting GLP-1 agonist studied. | Product · Guide |
| Retatrutide | ~6 days (144 h) | Long | Triple agonist (GLP-1/GIP/glucagon) with C20 fatty acid modification. Extended PK profile similar to other acylated incretins. | Product · Guide |
| Tirzepatide | ~5 days (120 h) | Long | Dual GLP-1/GIP agonist with C20 fatty diacid enabling albumin binding. Once-weekly research dosing interval in clinical studies. | Product · Guide |
| IGF-1 LR3 | ~20–30 hours | Long | Long R3 variant has 13-amino acid extension + Arg→Glu substitution, reducing IGF-binding protein affinity. Much longer acting than native IGF-1 (~10 min). | Product · Guide |
| TB-500 | ~6–8 hours | Medium | Thymosin Beta-4 fragment (43 aa). Relatively stable due to size and structure. Studied in tissue repair and cytoskeletal dynamics. | Guide |
| Tesamorelin | ~26–38 minutes | Short | GHRH analog with trans-3-hexenoic acid modification. Short plasma half-life but triggers extended GH release lasting hours. | Product · Guide |
| MOTS-C | ~4–6 hours (est.) | Medium | Mitochondrial-derived peptide (16 aa). Limited PK data available; estimated from rodent studies. Activates AMPK signaling. | Product · Guide |
| GHK-Cu | ~minutes (rapid) | Short | Copper tripeptide (3 aa). Very short plasma half-life, but triggers gene expression changes that persist 24+ hours post-exposure. | Product · Guide |
| Ipamorelin | ~2 hours | Medium | Selective GH secretagogue (ghrelin receptor agonist). Minimal effect on cortisol or prolactin in research models. | Guide |
| Sermorelin | ~10–20 minutes | Short | GHRH(1-29) fragment. Rapid proteolytic degradation. Stimulates pulsatile GH release mimicking physiological patterns. | Product · Guide |
| Semax | ~1–3 minutes (plasma) | Short | Synthetic ACTH(4-10) analog with Pro-Gly-Pro extension. Ultra-short plasma t½ but CNS effects persist hours via intracellular signaling cascades. | Product · Guide |
| BPC-157 | ~2 minutes (plasma) | Short | 15-amino acid gastric peptide. Extremely rapid plasma clearance, yet tissue-level biological activity extends well beyond plasma presence. | Product · Guide |
Sources: Published Phase I/II PK data, preclinical studies, and manufacturer technical documents. Half-life values are approximate and vary by species, dose, and route of administration.
The chart below illustrates relative half-lives on a logarithmic-inspired scale. Bars are proportional to duration, grouped by short (<1 hour), medium (1–12 hours), and long (>12 hours) categories.
Half-life is one of the most important pharmacokinetic parameters for designing research protocols. It directly impacts three critical experimental variables:
Half-life also informs how researchers interpret time-course data. A biological response observed 24 hours after administering a peptide with a 2-minute half-life suggests downstream signaling or tissue-level effects rather than direct receptor occupancy.
One of the most common misconceptions in peptide research is equating plasma half-life with duration of biological effect. These are distinct measurements:
For example, GHK-Cu has a plasma half-life measured in minutes, yet research shows it triggers gene expression changes in over 4,000 genes, with effects detectable 24+ hours after exposure. Similarly, tesamorelin has a ~30 minute plasma t½, but the growth hormone pulse it triggers lasts several hours.
This dissociation is especially pronounced with peptides that act as signaling triggers rather than sustained receptor occupants. The peptide initiates a cascade, and the cascade continues independently.
Several mechanisms explain why short-lived peptides can produce prolonged biological effects:
For researchers, this means plasma PK data alone is insufficient for predicting experimental outcomes. Tissue distribution studies, receptor occupancy assays, and downstream biomarker measurements provide a more complete picture of a peptide's functional timeline.
Peptide half-life refers to the time required for the plasma concentration of a peptide to decrease by 50% after administration. In research settings, this pharmacokinetic parameter helps investigators determine dosing intervals, predict steady-state concentrations, and design experimental protocols. Half-life is influenced by enzymatic degradation, renal clearance, protein binding, and molecular modifications such as fatty acid acylation or PEGylation.
Among commonly studied research peptides, semaglutide has the longest plasma half-life at approximately 7 days, followed by retatrutide at roughly 6 days and tirzepatide at approximately 5 days. These extended half-lives result from deliberate molecular engineering—specifically, fatty acid acylation that enables reversible albumin binding, which shields the peptide from renal clearance and enzymatic degradation.
Peptides with short plasma half-lives—such as BPC-157 (~2 minutes), ipamorelin (~2 hours), and sermorelin (~10–20 minutes)—are rapidly degraded by circulating proteases and cleared by the kidneys. Their small molecular size and lack of protective modifications expose them to rapid enzymatic breakdown. Research protocols for these peptides typically require more frequent dosing to maintain consistent plasma concentrations, though some researchers argue that pulsatile exposure may be more physiologically relevant for certain applications.
No. Half-life and potency are independent pharmacological parameters. Half-life describes how long a peptide remains in circulation, while potency refers to the concentration required to produce a specific biological effect at its target receptor. A peptide with a short half-life can be highly potent—BPC-157, for example, has a plasma half-life of only ~2 minutes but demonstrates significant biological activity in research models at low concentrations. Conversely, a long half-life does not guarantee greater efficacy; it simply means the compound persists longer in the system.
Source: PeptidesATX Research Library · This article is part of the PeptidesATX research knowledge base covering peptide pharmacology, supplier evaluation, and laboratory research compounds.
All peptides referenced in this guide are available as research-grade compounds with Certificates of Analysis, third-party purity testing, and same-day shipping from Austin, TX. See our guide to choosing a peptide supplier for what to verify before ordering.
Browse Research PeptidesDisclaimer: All compounds referenced in this article are intended for laboratory research use only. They are not approved for human or veterinary use by the FDA or any regulatory agency. Half-life values are approximate and derived from published pharmacokinetic literature. Actual values may vary depending on species, route of administration, dose, and experimental conditions. Nothing in this article constitutes medical advice or dosing guidance.